Akums Drugs and Pharmaceuticals Limited (AKUMS) AI Stock Analysis

• Market Cap: ₹70.30B
• Dividend Yield: N/A
• Average Volume (3M): 11.50K
• Price to Earnings (P/E): 21.6
• Beta (1Y): 1.54
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: IN
• Employees: 7,536
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 2.60
• Shares Outstanding: 157,393,980
• 10 Day Avg. Volume: 12,021
• 30 Day Avg. Volume: 11,497
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 63 Neutral
• Price Target: ₹448.00 ▲(6.64% Upside)

The overall stock score for Akums Drugs and Pharmaceuticals Limited is driven primarily by strong financial performance, with notable revenue growth and improved profitability. However, technical indicators suggest a bearish trend, and the valuation is moderate without a dividend yield to attract income investors. The absence of earnings call insights and corporate events did not impact the score.

Positive Factors

Patent for Innovative Treatment

Securing a patent for a novel GERD treatment underscores Akums' commitment to innovation, potentially strengthening its market position and offering a competitive edge in the pharmaceutical industry.

Expansion in European Market

Establishing a subsidiary in Malta enhances Akums' presence in Europe, opening new growth avenues and strengthening its international operations, which is crucial for long-term market expansion.

Improved Profit Margins

Improved profit margins indicate better cost management and pricing power, enhancing profitability and financial health, which supports sustainable growth.

Negative Factors

Operational Challenges

A decline in EBIT margin suggests operational inefficiencies, which could impact profitability if not addressed, posing a risk to long-term financial performance.

Decreased Operating Cash Flow

A decrease in operating cash flow may indicate challenges in cash generation, potentially affecting liquidity and the ability to fund future growth initiatives.

Absence of Earnings Call Insights

Lack of earnings call insights limits transparency and investor understanding of management's strategic direction, which can affect investor confidence and decision-making.

Akums Drugs and Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

Akums Drugs and Pharmaceuticals Limited (AKUMS) is a leading Indian pharmaceutical manufacturer and exporter, specializing in the production of a wide range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). Established in 2004, the company primarily operates in the sectors of prescription medicines, over-the-counter (OTC) products, and nutraceuticals. AKUMS is known for its commitment to quality and innovation, offering a diverse portfolio that includes formulations across various therapeutic segments such as cardiology, gynecology, and dermatology.

How the Company Makes Money

Akums generates revenue through the manufacture and sale of pharmaceutical products, including generics and branded formulations. The company has established multiple revenue streams, including direct sales to pharmacies and hospitals, partnerships with global pharmaceutical companies for contract manufacturing, and export of its products to international markets. Additionally, AKUMS benefits from collaborations with healthcare providers and distributors, which help widen its market reach. The company's focus on research and development also allows it to introduce new products, further enhancing its revenue potential.

Akums Drugs and Pharmaceuticals Limited Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	40.71B	40.20B	34.75B	36.47B
Gross Profit	16.05B	14.37B	11.67B	12.69B
EBITDA	5.29B	1.31B	3.09B	-821.80M
Net Income	3.38B	-40.35M	948.55M	-2.53B
Balance Sheet
Total Assets	41.13B	35.16B	32.67B	30.69B
Cash, Cash Equivalents and Short-Term Investments	5.82B	2.88B	1.50B	1.03B
Total Debt	882.12M	5.65B	6.19B	3.95B
Total Liabilities	10.50B	27.96B	25.43B	24.44B
Stockholders Equity	30.47B	7.09B	7.17B	6.22B
Cash Flow
Free Cash Flow	1.93B	1.87B	-1.52B	-2.26B
Operating Cash Flow	4.65B	4.98B	1.77B	318.54M
Investing Cash Flow	-5.48B	-3.30B	-3.05B	-2.35B
Financing Cash Flow	727.88M	-1.08B	1.25B	2.36B

Akums Drugs and Pharmaceuticals Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 420.10
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AKUMS, the sentiment is Negative. The current price of 420.1 is below the 20-day moving average (MA) of 440.78, below the 50-day MA of 436.89, and below the 200-day MA of 489.86, indicating a neutral trend. The MACD of 4.65 indicates Negative momentum. The RSI at 54.26 is Neutral, neither overbought nor oversold. The STOCH value of 41.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:AKUMS.

Akums Drugs and Pharmaceuticals Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INDRAMEDCO	69 Neutral	₹37.83B	21.65	―	0.96%	6.51%	18.24%
BAFNAPH	65 Neutral	₹3.31B	37.74	―	―	-0.77%	2055.99%
WANBURY	64 Neutral	₹7.63B	14.33	―	―	8.92%	-5.56%
AKUMS	63 Neutral	₹70.30B	21.57	―	―	―	―
BALPHARMA	58 Neutral	₹1.16B	14.25	―	1.62%	-9.07%	5.36%
KOPRAN	57 Neutral	₹7.21B	40.94	―	1.96%	-6.96%	-66.75%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Akums Drugs and Pharmaceuticals Limited Corporate Events

Akums Closes Trading Window Ahead of Q3 FY2025 Unaudited Results

Akums Drugs and Pharmaceuticals Limited has announced the closure of its trading window for designated persons and their immediate relatives from 1 January 2026 until 48 hours after the declaration of its unaudited financial results for the quarter ending 31 December 2025, in line with SEBI (Prohibition of Insider Trading) Regulations, 2015 and its internal code of conduct on insider trading. The company added that the date of the board meeting to consider and approve these quarterly unaudited results will be communicated separately, underscoring its adherence to regulatory norms governing disclosure and trading in its securities.

Akums Secures Patent for Innovative GERD Treatment

Akums Drugs and Pharmaceuticals Limited has been granted a patent for its innovative Dual Release Gastro-Resistant Composition, a next-generation proton pump inhibitor (PPI) tablet designed to treat gastroesophageal reflux disease (GERD). This new formulation, which releases medication in two phases, aims to provide extended relief from GERD symptoms, improving patient compliance and quality of life. The development of this advanced, once-daily tablet underscores Akums’ commitment to offering patient-friendly therapies for chronic acid-related disorders, potentially enhancing its market position in the pharmaceutical industry.

Akums Drugs Expands with New Subsidiary in Malta

Akums Drugs and Pharmaceuticals Limited has announced the incorporation of a wholly owned subsidiary in Malta, named Akums Healthcare Malta Private Limited. This strategic move is expected to enhance the company’s presence in the European market, potentially opening new avenues for growth and strengthening its international operations.

Akums Expands with New Joint Venture in Zambia

Akums Drugs and Pharmaceuticals Limited has announced the incorporation of a joint venture company in Zambia, named Akums Healthcare (Zambia) Private Limited. This strategic move is expected to enhance Akums’ market presence in the African region, potentially expanding its operational footprint and strengthening its industry positioning.